NYSE:WAT - Waters Stock Price, News, & Analysis

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters declared that its board has initiated a share buyback plan on Tuesday, April 24th 2018, which allows the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 18.2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

Waters Co. (NYSE:WAT) released its earnings results on Tuesday, July, 24th. The medical instruments supplier reported $1.95 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.92 by $0.03. The medical instruments supplier earned $596.20 million during the quarter, compared to analyst estimates of $598.73 million. Waters had a net margin of 2.12% and a return on equity of 27.85%. Waters's revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.76 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, October, 23rd 2018. View Earnings Estimates for Waters.

Waters issued an update on its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share guidance of $8.05-8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.18. Waters also updated its Q3 guidance to $1.85-1.95 EPS.

16 brokers have issued 1-year price targets for Waters' shares. Their predictions range from $180.00 to $230.00. On average, they expect Waters' stock price to reach $205.50 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price. View Analyst Price Targets for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Waters.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and Eyepoint Pharmaceuticals (EYPT).

Media headlines about WAT stock have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Waters earned a media and rumor sentiment score of 0.13 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 46.36 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Waters.

Waters' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.30%), Massachusetts Financial Services Co. MA (6.09%), Fundsmith Equity Fund L.P. (6.14%), Bank of New York Mellon Corp (5.56%), Baillie Gifford & Co. (3.26%) and Janus Henderson Group PLC (2.67%). Company insiders that own Waters stock include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Veritas Asset Management LLP, Massachusetts Financial Services Co. MA, Renaissance Technologies LLC, American Century Companies Inc., Millennium Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was purchased by a variety of institutional investors in the last quarter, including Fundsmith Equity Fund L.P., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Wells Fargo & Company MN, Assenagon Asset Management S.A., Schroder Investment Management Group, Select Equity Group L.P. and Mawer Investment Management Ltd.. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $187.44.

Waters has a market capitalization of $14.45 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]